School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, No. 232, Waihuandong Road, Higher Education Mega Center, Guangzhou, 510006, PR China.
The Sixth Clinical Medical College of Guangzhou University of Chinese Medicine, No. 6001, Beihuan Avenue, Futian District, Shenzhen, 518034, PR China.
J Ethnopharmacol. 2024 Jan 10;318(Pt B):116943. doi: 10.1016/j.jep.2023.116943. Epub 2023 Aug 1.
Yi Qi Chu Tan Formula (YQCTF), a prescription consisting of eight traditional Chinese medicine for treating lung cancer, has been clinically proven to be effective in improving the life quality and prolonging the survival time of non-small cell lung cancer (NSCLC) patients.
This study aimed to evaluate the therapeutic efficacy of YQCTF on NSCLC mice model and further explore its therapeutic targets by using network pharmacology, proteomics and pharmacodynamic methodologies.
The network pharmacology analysis was firstly conducted to screen out the potential active ingredients and therapeutic targets of YQCTF against NSCLC. Three kinds of extracts, i.e. the water extract (WE), water extraction-alcohol precipitation (WEAP) and alcohol extract (AE) of YQCTF were prepared, which chemical compositions were subsequently analyzed by using ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS), and which anti-neoplastic efficacy was examined on NSCLC mice model. Mice tumor tissues were collected for proteomics analysis, and the immunomodulatory effects of YQCTF extracts on the tumor microenvironment (TME) were further validated by using flow cytometry, immunofluorescence, ELISA and Western blot.
Network pharmacology identified 60 conjunct genes and ample cancer-related signaling pathways as potential therapeutic targets of YQCTF. Protein-protein interaction (PPI), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that YQCTF might negatively regulate cancer-related inflammation. UPLC-MS/MS analysis showed that the main components of YQCTF include at least ginsenosides, solasodine, solamargine, solasonine, peimisine, peiminine, peimine and sipeimine-3β-D-glucosihde. All kinds of YQCTF extracts significantly inhibited the growth of lung cancer allograft and regulated the ratio of immune cells in tumor tissues, i.e. upregulated the fractions of T cells, promoted the maturation of dendritic cells (DCs), increased the M1/M2 ratio of tumor-related macrophages, but reduced the number of Tregs and immunosuppressive neutrophils. Proteomics identified neutrophils to be the most prominently enriched target linked to NETs formation in mice tumor tissue, which is verified by the downregulation of neutrophil recruiting factors involving IL-6, HIF-1α and IL-8, as well as the decreases of NETs-related biomarkers including H3cit, MPO, CD18, MMP9 and ICAM-1 in immunofluorescence, ELISA and Western blot analysis.
YQCTF inhibited the progress of mice NSCLC allograft, suppressed the pro-tumorigenic tumor-associated neutrophils and improved the tumor immune microenvironment (TIME).
益气除痰方(YQCTF)是一种由 8 种中药组成的处方,用于治疗肺癌,已在临床上证明能有效提高非小细胞肺癌(NSCLC)患者的生活质量和延长生存时间。
本研究旨在通过网络药理学、蛋白质组学和药效学方法,评估 YQCTF 对 NSCLC 小鼠模型的治疗效果,并进一步探讨其治疗靶点。
首先进行网络药理学分析,筛选出 YQCTF 治疗 NSCLC 的潜在活性成分和治疗靶点。制备 YQCTF 的 3 种提取物,即水提取物(WE)、水提醇沉(WEAP)和醇提取物(AE),随后采用超高效液相色谱-质谱/质谱联用(UPLC-MS/MS)分析其化学成分,并在 NSCLC 小鼠模型中检测其抗肿瘤功效。收集小鼠肿瘤组织进行蛋白质组学分析,并通过流式细胞术、免疫荧光、ELISA 和 Western blot 进一步验证 YQCTF 提取物对肿瘤微环境(TME)的免疫调节作用。
网络药理学鉴定了 60 个共同基因和大量癌症相关信号通路作为 YQCTF 的潜在治疗靶点。蛋白质-蛋白质相互作用(PPI)、基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析表明,YQCTF 可能负调控与癌症相关的炎症。UPLC-MS/MS 分析表明,YQCTF 的主要成分至少包括人参皂苷、茄碱、澳洲茄碱、澳洲茄边碱、佩米辛、佩米宁、佩米宁和 sipeimine-3β-D-葡萄糖苷。YQCTF 的各种提取物均能显著抑制肺癌异体移植的生长,并调节肿瘤组织中免疫细胞的比例,即上调 T 细胞的比例,促进树突状细胞(DC)的成熟,增加肿瘤相关巨噬细胞的 M1/M2 比值,减少 Treg 和免疫抑制性中性粒细胞的数量。蛋白质组学鉴定出中性粒细胞是在小鼠肿瘤组织中与 NETs 形成最显著富集的靶标,通过下调涉及白细胞介素 6(IL-6)、低氧诱导因子 1α(HIF-1α)和白细胞介素 8(IL-8)的中性粒细胞募集因子,以及免疫荧光、ELISA 和 Western blot 分析中 NETs 相关生物标志物 H3cit、MPO、CD18、MMP9 和 ICAM-1 的减少,验证了这一点。
YQCTF 抑制了小鼠 NSCLC 异体移植的进展,抑制了促肿瘤发生的肿瘤相关中性粒细胞,并改善了肿瘤免疫微环境(TIME)。